irinotecan has been researched along with imatinib mesylate in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (71.43) | 29.6817 |
| 2010's | 4 (19.05) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Nokihara, H; Ohe, Y | 1 |
| Adams, R; Albritton, K; Coffin, C; Goldsby, R; Pulsipher, M; Wagner, L | 1 |
| Patel, SR | 1 |
| Burnakis, TG | 1 |
| Buchdunger, E; Germain, GS; Harwood, FC; Houghton, PJ; Schuetz, JD; Stewart, CF; Traxler, P | 1 |
| Hayakawa, Y | 1 |
| Gillenwater, HH; Wolf, T | 1 |
| Glisson, BS; Johnson, FM; Krug, LM; Patel, J; Peeples, B; Prieto, VG; Shoaf, S; Tamboli, P; Tran, HT | 1 |
| Buxhofer-Ausch, V; Hinterberger, W; Hinterberger-Fischer, M | 1 |
| Borner, MM | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kobayashi, H; Mano, H; Tsunoda, S | 1 |
| Bucana, CD; Fidler, IJ; Kitadai, Y; Kuwai, T; Nakamura, T; Sasaki, T | 1 |
| Fujiwara, Y; Hisamoto, A; Hotta, K; Ichihara, E; Kiura, K; Kozuki, T; Ohashi, K; Osawa, M; Shibayama, T; Tabata, M; Tada, A; Takahashi, K; Takata, S; Takeyama, M; Takigawa, N; Tanimoto, M; Umemura, S | 1 |
| Burris, HA; Grapski, R; Greco, FA; Hainsworth, JD; Mallidi, PV; Meng, C; Schreeder, M; Simons, L; Spigel, DR; Yardley, DA | 1 |
| Chen, W; Gadgeel, SM; Kalemkerian, GP; Kraut, MJ; Ramnath, N; Ruckdeschel, JC; Schneider, BJ; Worden, FP; Wozniak, AJ; Zhang, X | 1 |
| Chayama, K; Kitadai, Y; Kodama, M; Ohara, E; Ohnishi, M; Shinagawa, K; Sumida, T; Tanaka, M; Tanaka, S; Yasui, W | 1 |
| Jeong, S; Jeong, YA; Jo, MJ; Kim, BR; Kim, JL; Lee, DH; Na, YJ; Oh, SC; Park, SH | 1 |
| Hu, Y; Lu, J; Luo, P; Qian, R; Yang, X; Zhang, Y | 1 |
| Basit, A; Fan, PW; Khojasteh, SC; Li, AP; Murray, BP; Prasad, B; Smith, BJ; Takahashi, RH; Thummel, KE; Wolford, C; Zhang, H | 1 |
4 review(s) available for irinotecan and imatinib mesylate
| Article | Year |
|---|---|
[Recent progress in the treatment of ED small cell lung cancer].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Piperazines; Pyrimidines; Vincristine | 2002 |
Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas.
Topics: Antineoplastic Agents; Benzamides; Camptothecin; Dacarbazine; Deoxycytidine; Dioxoles; Gemcitabine; Humans; Imatinib Mesylate; Irinotecan; Isoquinolines; Piperazines; Pyrimidines; Sarcoma; Temozolomide; Tetrahydroisoquinolines; Trabectedin | 2002 |
Treatment options for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiotherapy, Adjuvant; Risk Factors; Sex Distribution; Smoking; Survival Rate; Treatment Outcome; United States | 2004 |
[Molecular targets in colon cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolones; Receptors, Platelet-Derived Growth Factor; Receptors, Somatomedin; Signal Transduction; Sirolimus; Sunitinib | 2006 |
3 trial(s) available for irinotecan and imatinib mesylate
| Article | Year |
|---|---|
Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Carcinoma, Small Cell; Cisplatin; Female; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Male; Middle Aged; Piperazines; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-kit; Pyrimidines | 2006 |
Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Virginia | 2007 |
Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2010 |
14 other study(ies) available for irinotecan and imatinib mesylate
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Unexpected pleural effusions in 3 pediatric patients treated with STI-571.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Camptothecin; Child; Combined Modality Therapy; Edema; Enzyme Inhibitors; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Lung Neoplasms; Male; Neoplasm Proteins; Neuroectodermal Tumors, Primitive; Piperazines; Pleural Effusion; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Sarcoma, Ewing; Testis; Topotecan | 2002 |
Comment: Usefulness of herbal and dietary supplement references.
Topics: Benzamides; Camptothecin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dietary Supplements; Drug Interactions; Humans; Hypericum; Imatinib Mesylate; Irinotecan; Phytotherapy; Piperazines; Plant Preparations; Pyrimidines; Reference Books | 2003 |
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Bone Neoplasms; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Irinotecan; Neoplasm Proteins; Osteosarcoma; Piperazines; Pyrimidines; Topotecan | 2004 |
[Structure-activity relationship analysis].
Topics: Antineoplastic Agents; Benzamides; Camptothecin; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Imatinib Mesylate; Irinotecan; Macrolides; Oligopeptides; Paclitaxel; Piperazines; Pyrimidines; Quinazolines; Structure-Activity Relationship; Taxoids; Topotecan; Vinblastine | 2004 |
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diagnosis, Differential; Disease Progression; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Cytarabine; Depsipeptides; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Imatinib Mesylate; Irinotecan; K562 Cells; Leukemia; Lymphoma; Mercaptopurine; Piperazines; Pyrimidines; Time Factors | 2007 |
Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Camptothecin; Carcinoma; Cecum; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Synergism; Humans; Imatinib Mesylate; Irinotecan; Liver; Male; Mice; Mice, Nude; Pericytes; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Stromal Cells; Transplantation, Heterologous | 2006 |
Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gefitinib; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Piperazines; Pyrimidines; Quinazolines | 2007 |
Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, Western; Camptothecin; Cell Proliferation; Fluorescent Antibody Technique; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Male; Mice; Mice, Nude; Microscopy, Confocal; Neoplasm Metastasis; Neovascularization, Pathologic; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Imatinib‑induced apoptosis of gastric cancer cells is mediated by endoplasmic reticulum stress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endoplasmic Reticulum Stress; Endoribonucleases; Fluorouracil; Humans; Imatinib Mesylate; Irinotecan; JNK Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Stomach Neoplasms; Transcription Factor CHOP | 2019 |
Enhanced proliferation inhibition and apoptosis in glioma cells elicited by combination of irinotecan and imatinib.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Female; Glioma; Humans; Imatinib Mesylate; Irinotecan; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Rats; Tumor Burden; Tumor Suppressor Protein p53 | 2020 |
Regional Proteomic Quantification of Clinically Relevant Non-Cytochrome P450 Enzymes along the Human Small Intestine.
Topics: Adult; Carboxylesterase; Clopidogrel; Enzyme Assays; Female; Glucuronosyltransferase; Humans; Imatinib Mesylate; Intestinal Mucosa; Intestine, Small; Irinotecan; Male; Middle Aged; Proteomics; Sulfotransferases; Testosterone; Young Adult | 2020 |